Logo image of AMAM

NEW AMBRX BIOPHARMA INC (AMAM) Stock Price, Quote, News and Overview

NASDAQ:AMAM - Nasdaq - US6418711080 - Common Stock - Currency: USD

28  +0.02 (+0.07%)

After market: 28 0 (0%)

AMAM Quote, Performance and Key Statistics

NEW AMBRX BIOPHARMA INC

NASDAQ:AMAM (3/6/2024, 8:00:01 PM)

After market: 28 0 (0%)

28

+0.02 (+0.07%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High28.15
52 Week Low6.55
Market Cap12.42B
Shares443.47M
Float61.65M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-26 2024-03-26
IPO06-18 2021-06-18


AMAM short term performance overview.The bars show the price performance of AMAM in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60 80 100

AMAM long term performance overview.The bars show the price performance of AMAM in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300 400 500

The current stock price of AMAM is 28 USD. In the past month the price increased by 0.79%. In the past year, price increased by 188.96%.

NEW AMBRX BIOPHARMA INC / AMAM Daily stock chart

AMAM Latest News, Press Releases and Analysis

News Image
a year ago - Ambrx Biopharma Inc.

Ambrx Shareholders Approve Acquisition by Johnson & Johnson

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders...

News Image
a year ago - InvestorPlace

3 Dividend Stocks That Are Too Good to Ignore: Q1 Edition

Here are the three dividend stocks that will never disappoint you. Buy them while they trade at a discount.

News Image
a year ago - InvestorPlace

3 Stocks to Buy That Are Up 200% or More in 2024

Each of these stocks up 200% in 2024 offer unique upside opportunities for investors, including equity arbitrage plays.

News Image
a year ago - InvestorPlace

The 3 Biotech Stocks That Could Make Your February Unforgettable

After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.

News Image
a year ago - Halper Sadeh LLP

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AMAM, JNPR, INBX, RYZB

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image
a year ago - Kuehn Law, PLLC

Kuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law Firm

/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...

AMAM Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.77 335.67B
AMGN AMGEN INC 15.04 155.36B
VRTX VERTEX PHARMACEUTICALS INC 945.65 124.20B
GILD GILEAD SCIENCES INC 22.12 122.12B
REGN REGENERON PHARMACEUTICALS 15.34 76.60B
ARGX ARGENX SE - ADR N/A 38.95B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 34.95B
BNTX BIONTECH SE-ADR N/A 28.08B
ONC BEIGENE LTD-ADR N/A 23.76B
NTRA NATERA INC N/A 23.00B
BIIB BIOGEN INC 8.73 20.76B
UTHR UNITED THERAPEUTICS CORP 15.52 15.78B

About AMAM

Company Profile

Ambrx Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in La Jolla, California and currently employs 66 full-time employees. The company went IPO on 2021-06-18. Ambrx Biopharma Inc. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. The company is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its ADC targeting Human epidermal growth factor receptor 2 (HER2). The company uses genetic code technology platform to discover and develop engineered precision biologics. Its genetic code technology platform allows to incorporate, in a site-specific manner, synthetic amino acids (SAA), into proteins within living cells. Its SAA incorporation technology is designed to develop a range of product candidate modality, such as modified cytokines and bispecific antibodies, and others.

Company Info

NEW AMBRX BIOPHARMA INC

10975 North Torrey Pines Road

La Jolla CALIFORNIA US

CEO: Feng Tian

Employees: 66

Company Website: https://ambrx.com/

Phone: 18588752400

AMAM FAQ

What is the stock price of AMAM?

The current stock price of AMAM is 28 USD.


What is the symbol for NEW AMBRX BIOPHARMA INC stock?

The exchange symbol of NEW AMBRX BIOPHARMA INC is AMAM and it is listed on the Nasdaq exchange.


On which exchange is AMAM stock listed?

AMAM stock is listed on the Nasdaq exchange.


Is AMAM a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for AMAM, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of AMAM.


Does AMAM stock pay dividends?

AMAM does not pay a dividend.


When does AMAM stock report earnings?

AMAM will report earnings on 2024-03-26.


What is the Price/Earnings (PE) ratio of AMAM?

AMAM does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.57).


AMAM Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to AMAM. When comparing the yearly performance of all stocks, AMAM is one of the better performing stocks in the market, outperforming 98.51% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

AMAM Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to AMAM. AMAM has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AMAM Financial Highlights

Over the last trailing twelve months AMAM reported a non-GAAP Earnings per Share(EPS) of -0.57. The EPS increased by -16% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -30.43%
ROE -34.09%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)-16%
Revenue 1Y (TTM)-0.8%

AMAM Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 76% to AMAM. The Buy consensus is the average rating of analysts ratings from 14 analysts.

For the next year, analysts expect an EPS growth of -159.66% and a revenue growth -57.14% for AMAM


Ownership
Inst Owners0.01%
Ins Owners8.9%
Short Float %N/A
Short RatioN/A
Analysts
Analysts75.71
Price Target29.07 (3.82%)
EPS Next Y-159.66%
Revenue Next Year-57.14%